Patients

What is HRD Status?

Homologous recombination (HR) is the way our body fixes damaged DNA. When homologous recombination is not able to fix damaged DNA, this is called homologous recombination deficiency (HRD). Approximately 50% of all ovarian cancer tumors have homologous recombination deficiency. Your HRD status will be determined one of two ways, first by analyzing for a change in your BRCA1 and BRCA2 genes, and second through a specialized tool known as genomic instability.

What does HRD Status Mean to You?

If you are found to be HRD+, your tumor is more likely to respond to a type of drug called a PARP inhibitor than those tumors that are not HRD+. These ovarian tumors are more likely to shrink when a PARP inhibitor is used.

Patients with ovarian cancer

What are PARP inhibitors?

PARP inhibitors, or poly (ADP-ribose) polymerase inhibitors, are pills that are taken by mouth after being prescribed to you by a physician. They may be used to treat women with ovarian cancer. 

PARP inhibitors work by blocking DNA from being repaired. If the DNA damage cannot be repaired, the cancer cell will be killed. If a cancer cell is like a balloon, a PARP inhibitor is like the needle trying to pop it.

How Does myChoice® CDx Help?

myChoice® CDx looks at ovarian tumors for mutation in the BRCA1 and BRCA2 genes as well as for features associated with genomic instability. The goal is to determine which women would benefit the most from PARP inhibitor therapy. This information helps your health care provider to make the best treatment decisions for you personally.

myChoice® CDx does not analyze your tumor to determine whether your ovarian cancer is a result of an inherited gene mutation. Myriad also offers germline genetic testing to determine if there is an inherited risk.

Myriad is committed to providing the right results at the right time so you can make the right decisions for your journey

Accurate

myChoice® is an FDA-approved tumor test for ovarian cancer. It has been validated in multiple clinical studies and is the only tumor test for HRD status recommended by national guidelines.

Affordable

myChoice® CDx has broad insurance coverage. Myriad will work with your insurance provider to help you get the appropriate coverage. The Myriad Promise is our commitment to provide patients with accurate and affordable results. For more information, visit MyriadPromise.com

Accessible

Myriad is committed to providing myChoice® CDx results as quickly as possible. Our results are easy to read and provide you and your provider with the necessary information to make important medical decisions.
References
  1. American Cancer Society. (http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-key-statistics).
  2. Lancaster, JM et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncology 136(2015)3–7.
  3. Walsh, T et al. Proceedings of the National Academy of Sciences of the United States of America. 18032-18037, November 1, 2011. Vol 108, no 44.
  4. Swisher, E. Beyond BRCA: Other Genetic Markers for High Risk Women and Prophylactic Surgery for High Risk Women. SGO Annual Meeting 2016.